The global blood purification equipment market size is calculated at USD 20.77 billion in 2025 and is forecasted to reach around USD 35.99 billion by 2034, accelerating at a CAGR of 6.30% from 2025 to 2034. The blood purification equipment market is experiencing significant growth, driven by the increasing prevalence of chronic kidney disease, rising demand for dialysis and extracorporeal therapies, and rapid technological advancements in filtration systems
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Blood Purification Equipment Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Blood Purification Equipment Market, by Modality
8.1.1 Hemodialysis (HD)
8.1.1.1. Market Revenue and Forecast
8.1.2. Continuous Renal Replacement Therapy (CRRT)
8.1.2.1. Market Revenue and Forecast
8.1.3. Hemoperfusion
8.1.3.1. Market Revenue and Forecast
8.1.4. Plasma Exchange / Apheresis (TPE / TPA)
8.1.4.1. Market Revenue and Forecast
8.1.5. Immunoadsorption
8.1.5.1. Market Revenue and Forecast
8.1.6. Others / Hybrid Modalities
8.1.6.1. Market Revenue and Forecast
9.1. Blood Purification Equipment Market, by Application/Clinical Indication
9.1.1. Acute Kidney Injury (AKI)
9.1.1.1. Market Revenue and Forecast
9.1.2. Chronic Kidney Disease / End-Stage Renal Disease
9.1.2.1. Market Revenue and Forecast
9.1.3. Sepsis and Septic Shock
9.1.3.1. Market Revenue and Forecast
9.1.4. Infectious Diseases
9.1.4.1. Market Revenue and Forecast
9.1.5. Autoimmune & Neurological Disorders
9.1.5.1. Market Revenue and Forecast
9.1.6. Toxin Removal / Drug Overdose
9.1.6.1. Market Revenue and Forecast
9.1.7. Others
9.1.7.1. Market Revenue and Forecast
10.1. Blood Purification Equipment Market, by End-User
10.1.1. Hospitals (General & Specialty)
10.1.1.1. Market Revenue and Forecast
10.1.2. Dialysis Centers
10.1.2.1. Market Revenue and Forecast
10.1.3. Dialysis Centers
10.1.3.1. Market Revenue and Forecast
10.1.4. Ambulatory Surgical Centers
10.1.4.1. Market Revenue and Forecast
10.1.5. Home-care Settings
10.1.5.1. Market Revenue and Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Modality
11.1.2. Market Revenue and Forecast, by Application/Clinical Indication
11.1.3. Market Revenue and Forecast, by End-User
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Modality
11.1.4.2. Market Revenue and Forecast, by Application/Clinical Indication
11.1.4.3. Market Revenue and Forecast, by End-User
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Modality
11.1.5.2. Market Revenue and Forecast, by Application/Clinical Indication
11.1.5.3. Market Revenue and Forecast, by End-User
11.2. Europe
11.2.1. Market Revenue and Forecast, by Modality
11.2.2. Market Revenue and Forecast, by Application/Clinical Indication
11.2.3. Market Revenue and Forecast, by End-User
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Modality
11.2.4.2. Market Revenue and Forecast, by Application/Clinical Indication
11.2.4.3. Market Revenue and Forecast, by End-User
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Modality
11.2.5.2. Market Revenue and Forecast, by Application/Clinical Indication
11.2.5.3. Market Revenue and Forecast, by End-User
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Modality
11.2.6.2. Market Revenue and Forecast, by Application/Clinical Indication
11.2.6.3. Market Revenue and Forecast, by End-User
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Modality
11.2.7.2. Market Revenue and Forecast, by Application/Clinical Indication
11.2.7.3. Market Revenue and Forecast, by End-User
11.3. APAC
11.3.1. Market Revenue and Forecast, by Modality
11.3.2. Market Revenue and Forecast, by Application/Clinical Indication
11.3.3. Market Revenue and Forecast, by End-User
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Modality
11.3.4.2. Market Revenue and Forecast, by Application/Clinical Indication
11.3.4.3. Market Revenue and Forecast, by End-User
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Modality
11.3.5.2. Market Revenue and Forecast, by Application/Clinical Indication
11.3.5.3. Market Revenue and Forecast, by End-User
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Modality
11.3.6.2. Market Revenue and Forecast, by Application/Clinical Indication
11.3.6.3. Market Revenue and Forecast, by End-User
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Modality
11.3.7.2. Market Revenue and Forecast, by Application/Clinical Indication
11.3.7.3. Market Revenue and Forecast, by End-User
11.4. MEA
11.4.1. Market Revenue and Forecast, by Modality
11.4.2. Market Revenue and Forecast, by Application/Clinical Indication
11.4.3. Market Revenue and Forecast, by End-User
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Modality
11.4.4.2. Market Revenue and Forecast, by Application/Clinical Indication
11.4.4.3. Market Revenue and Forecast, by End-User
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Modality
11.4.5.2. Market Revenue and Forecast, by Application/Clinical Indication
11.4.5.3. Market Revenue and Forecast, by End-User
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Modality
11.4.6.2. Market Revenue and Forecast, by Application/Clinical Indication
11.4.6.3. Market Revenue and Forecast, by End-User
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Modality
11.4.7.2. Market Revenue and Forecast, by Application/Clinical Indication
11.4.7.3. Market Revenue and Forecast, by End-User
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Modality
11.5.2. Market Revenue and Forecast, by Application/Clinical Indication
11.5.3. Market Revenue and Forecast, by End-User
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Modality
11.5.4.2. Market Revenue and Forecast, by Application/Clinical Indication
11.5.4.3. Market Revenue and Forecast, by End-User
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Modality
11.5.5.2. Market Revenue and Forecast, by Application/Clinical Indication
11.5.5.3. Market Revenue and Forecast, by End-User
12.1. Cytosorbents Corporation
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Cytosorbents Corporation
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Cerus Corporation
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Jafron Biomedical Co., Ltd.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Spectra Medical, Inc.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. B. Braun Melsungen AG
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. and Nikkiso Co, Ltd
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. ExThera Medical Corporation
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Aethlon Medical, Inc.
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Fresenius SE & Co. KGaA
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Get a Sample
Report Description
Get a Sample
Report Description